Testosterone insufficiency increases death risk in older men

Article

Testosterone insufficiency in older men is associated with increased risk of death over the following 20 years, independent of multiple risk factors and several pre-existing health conditions, according to researchers from the University of California, San Diego School of Medicine.

Testosterone insufficiency in older men is associated with increased risk of death over the following 20 years, independent of multiple risk factors and several pre-existing health conditions, according to researchers from the University of California, San Diego School of Medicine.

Gail A. Laughlin, MD, and colleagues studied 794 men, age 50 to 91 years, who had serum testosterone measurements at baseline (1984-1987) and followed them for mortality through July 2004.

During an average 11.8 year follow-up, 538 deaths occurred. Men whose total testosterone levels were in the lowest quartile (<241 ng/dL) were 40% more likely to die than were those with higher levels, independent of age, adiposity, and lifestyle (HR=1.40; 95% CI, 1.14–1.71). Additional adjustment for health status markers, lipids, lipoproteins, blood pressure, glycemia, adipocytokines, and estradiol levels had minimal effect on results.

The low testosterone-mortality association was also independent of the metabolic syndrome, diabetes, and prevalent cardiovascular disease, but was attenuated by adjustment for IL-6 and C-reactive protein. In cause-specific analyses, low testosterone predicted increased risk of cardiovascular (HR, 1.38; 95% CI, 1.02- 1.85) and respiratory disease (HR, 2.29; 95% CI, 1.25–4.20) mortality, but was not significantly related to cancer death (HR, 1.34; 95% CI, 0.89, 2.00). Results were similar for bioavailable testosterone.

The study will appear in the Journal of Clinical Endocrinology & Metabolism.

Related Videos
Kevin M. Wymer, MD
Video 7 - "Multidisciplinary Collaboration and Expert Insights in the Management of Advanced Prostate Cancer"
Video 6 - "Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape"
Video 5 - "Targeting the Androgen Receptor Pathway and Overcoming Treatment Resistance in Advanced Prostate Cancer"
Video 4 - "Androgen Receptor Signaling and Its Role in Driving Prostate Cancer Metastasis"
Video 3 - "Treatment Selection in Metastatic and Castration Resistant Prostate Cancer: Optimizing Outcomes and Preserving Patient Quality of Life"
Video 2 - "Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer"
Video 1 - "Metastatic Prostate Cancer: Background and Patient Prognosis"
Related Content
© 2024 MJH Life Sciences

All rights reserved.